Navigation Links
MiMedx Announces Record First Quarter 2013 Results
Date:5/1/2013

l measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Revenue Breakdown The Company distinguishes its revenue between three primary regenerative medicine specialties, "Wound Care," "Surgical & Sports Medicine," and "Other," and reports its revenue in these categories. Revenue for the Company's EpiFix® grafts comprises the Wound Care category. Its Surgical & Sports Medicine specialty is comprised of the Company's injectable, orthopedic and surgical applications for its AmnioFix® grafts. The "Other" category of the MiMedx regenerative medicine specialties includes the Company's tissue revenue from its dental and ophthalmic applications and products from its HydroFix® technology. In the quarter, 54% of MiMedx sales volume was for Wound Care, 40% for Surgical and Sports Medicine and 6% for "Other."

Outlook for Second Quarter and Full Year 2013The Company reaffirmed its previously communicated goals for second quarter of 2013 revenue to be in the range of $11.5 million to $13.5 million and full year 2013 revenue to be in the range of $50 million to $60 million. The point within the range of revenue goals will be largely dependent on whether and how quickly the remaining Medicare intermediaries begin to reimburse for the Company's EpiFix® allografts recognizing that there are a number of factors that are beyond the Company's ability to influence.

Earnings CallMiMedx management will host a live broadcast of its first quarter results conference call on Wednesday, May 1, 2013, beginning at 10:30 a.m. eastern time. A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
2. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
3. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
4. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
5. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
6. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
7. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
8. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
9. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
10. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
11. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
(Date:10/22/2014)... Oct. 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) ... million people worldwide are living with diabetes, with  that ... 2030.  The global market for diabetes treatments is approximately ... people worldwide died from pancreatic cancer.  Pancreatic cancer is ... cancer in the United States , ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... EMERYVILLE, Calif., Dec. 2 Bionovo, Inc.,(Nasdaq: BNVI ), ... effective drugs in the areas of women,s health and,cancer, announced that ... of the Company at the 20th Annual Piper Jaffray Health,Care Conference ... will be held at,the New York Palace Hotel in New York ...
... Va., and SAN DIEGO, Dec. 2 The Patient,Advocate ... is,pleased to announce the launch of the Lymphedema CareLine ... toll-free patient/provider,hotline designed to provide information and assistance to ... for post-treatment side effects such as,lymphedema (swelling due to ...
... Corporation (Nasdaq: MATK ) announced that it intends to ... on December 11, 2008, at approximately 4:00 p.m. Eastern Time (ET). ... a conference call to discuss these results with investors. All ... visiting Martek,s web site at http://investors.martek.com . , ...
Cached Biology Technology:Bionovo to Present at the Piper Jaffray Healthcare Conference 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 3
(Date:10/22/2014)... Oct. 20, 2014 The Nano-Bio Manufacturing Consortium ... Force Research Laboratory (AFRL), has chosen a project proposed ... the University of Arizona College of Medicine – ... AzCIM project,s goal is to assess different sweat collection ... volumes of sweat under a variety of human-body conditions, ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2
... the Welsh national flower, which could offer hope for sufferers ... by Cardiff University's Manufacturing Engineering Centre (MEC). , Alzheimer's disease ... per cent of all cases of dementia. Dementia affects one ... person in five over the age of 80. , Certain ...
... step closer to a technique to easily detect a ... The findings, currently online in the Proceedings of the ... of DNA into cell cultures and observing whether they ... proteins. , The technique could enable doctors to ...
... DNA molecule that is copied almost as efficiently as ... online edition of the Proceedings of the National Academy ... genetic mutations-tiny mistakes that occur during DNA replication-arise. The ... a professor of chemistry at Stanford and co-author of ...
Cached Biology News:Scientists closer to new cancer detection method 2Scientists closer to new cancer detection method 3DNA size a crucial factor in genetic mutations, study finds 2DNA size a crucial factor in genetic mutations, study finds 3
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Biology Products: